Abstract: Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for delivering therapy to an adrenal gland of a patient. The apparatuses, systems, and methods may include a plurality of stimulation elements arranged configured to deliver stimulation energy through at least one of the plurality of stimulation elements to modulate aldosterone levels within the patient.

Abstract: This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.

Abstract: Aspects of the present disclosure are directed toward apparatuses, systems, and methods for delivering therapy to an adrenal gland of a patient. The apparatuses, systems, and methods may include a housing and a plurality of electrodes arranged with the housing. In addition, one or more of the plurality of electrodes may deliver stimulation energy to modulate L-dopa release.

Abstract: Aspects of the present disclosure are directed toward apparatuses, systems, and methods for delivering therapy to an adrenal gland of a patient. The apparatuses, systems, and methods may include a lead body that attaches to a portion of the adrenal gland of the patient; and a plurality of electrodes arranged along the lead body. In addition, one or more of the plurality of electrodes may deliver stimulation energy to modulate catecholamine release from chromaffin cells within the adrenal gland.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: Various aspects of the present disclosure are directed toward apparatuses, systems, and methods for delivering therapy to an adrenal gland of a patient. The apparatuses, systems, and methods may include a plurality of stimulation elements arranged configured to deliver stimulation energy through at least one of the plurality of stimulation elements to modulate aldosterone levels within the patient.

Abstract: A prosthetic heart valve provided herein can include a kidney capsule tissue leaflet. In some cases, a prosthetic heart valve can include a plurality of leaflets secured together and retained within the expandable tubular member. The kidney capsule tissue can be obtained from a farm animal, such as a cow, pig, horse, goat, or sheep. In some cases, the kidney capsule tissue can be tensioned (e.g., bi-axially tensioned) and/or chemically cross-linked.

Abstract: Aspects of the present disclosure are directed toward apparatuses, systems, and methods for delivering therapy to an adrenal gland of a patient. The apparatuses, systems, and methods may include a housing and a plurality of electrodes arranged with the housing. In addition, one or more of the plurality of electrodes may deliver stimulation energy to modulate L-dopa release.

Abstract: Aspects of the present disclosure are directed towards apparatuses, systems, and methods that include at least one implantable medical device. The implantable medical device may include a leadless body portion configured to engage an adrenal gland of a patient and at least one electrode, arranged within the leadless body portion, configured to deliver stimulation energy to modulate catecholamine release from chromaffin cells within the adrenal gland.

Abstract: Aspects of the present disclosure are directed toward apparatuses, systems, and methods for delivering therapy to an adrenal gland of a patient. The apparatuses, systems, and methods may include a lead body that attaches to a portion of the adrenal gland of the patient; and a plurality of electrodes arranged along the lead body. In addition, one or more of the plurality of electrodes may deliver stimulation energy to modulate catecholamine release from chromaffin cells within the adrenal gland.

Abstract: This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system, through the gastrointestinal system, or redirected outside the body. The device may include a valve to control a flow of the fluid. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being metabolized and absorbed, thereby reducing the total caloric load to assist in weight management and/or for prevention/treatment of atherosclerosis.

Abstract: A prosthetic heart valve provided herein can include a kidney capsule tissue leaflet. In some cases, a prosthetic heart valve can include a plurality of leaflets secured together and retained within the expandable tubular member. The kidney capsule tissue can be obtained from a farm animal, such as a cow, pig, horse, goat, or sheep. In some cases, the kidney capsule tissue can be tensioned (e.g., bi-axially tensioned) and/or chemically cross-linked.

Abstract: The present disclosure relates to the field of tissue mapping and ablation. Specifically, the present disclosure relates to expandable medical devices for identifying and treating local anatomical abnormalities within a body lumen. More specifically, the present disclosure relates to systems and methods of focal treatment for overactive bladders.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system, through the gastrointestinal system, or redirected outside the body. The device may include a valve to control a flow of the fluid. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being metabolized and absorbed, thereby reducing the total caloric load to assist in weight management and/or for prevention/treatment of atherosclerosis.

Abstract: Methods and devices for redirecting at least a portion of a fluid from the mesenteric lymphatic system for elimination from the body are disclosed. The fluid may be redirected for elimination through the urinary system or redirected outside the body. The methods and devices disclosed may prevent a portion of a patient's dietary lipids, including cholesterol, from being absorbed, thereby reducing the total caloric load to assist in weight management.

Abstract: A processor circuit can be configured to obtain a first multidimensional vector. The first multidimensional vector can include dimensions corresponding to respective first conductivity characteristics obtained from different implantable electrode configurations associated with a subject. The processor circuit can also be configured to obtain a second multidimensional vector or vector space. The second multidimensional vector or vector space can include dimensions corresponding to respective second conductivity characteristics obtained from such different electrode configurations associated with the same or a different subject. The processor circuit can also provide a physiological status indicator that can be obtained at least in part by performing a vector comparison of the first multidimensional vector to the second multidimensional vector space or vector.

Abstract: A processor circuit can be configured to obtain a first multidimensional vector. The first multidimensional vector can include dimensions corresponding to respective first conductivity characteristics obtained from different implantable electrode configurations associated with a subject. The processor circuit can also be configured to obtain a second multidimensional vector or vector space. The second multidimensional vector or vector space can include dimensions corresponding to respective second conductivity characteristics obtained from such different electrode configurations associated with the same or a different subject. The processor circuit can also provide a physiological status indicator that can be obtained at least in part by performing a vector comparison of the first multidimensional vector to the second multidimensional vector space or vector.